- Published on
Toxicology – Baclofen Toxicity
Source
Baclofen is a prescription muscle relaxant used to treat spasticity in conditions such as spinal cord injury, cerebral palsy, and multiple sclerosis. It is available in oral form and can also be administered via intrathecal pumps for targeted delivery.
Typical Presentation
Toxicity may occur following overdose or misuse. Patients often present with progressive central nervous system depression, which may initially resemble intoxication and later advance to severe neurological impairment.
Clinical Features
Findings are consistent with a sedative-hypnotic toxidrome. Symptoms include drowsiness, poor coordination, ataxia, slurred speech, nausea, vomiting, and altered mental status. Cardiovascular effects may include either low or high blood pressure and slow or fast heart rate. Neurologically, decreased reflexes, muscle relaxation, coma, seizures, apnea, and respiratory arrest can occur. In some cases, paradoxical muscle rigidity or spasms may be seen. Severe toxicity is more likely with large ingestions and may require prolonged intensive care support.
Mechanism of Action
Baclofen acts as a GABA(B) receptor agonist, producing inhibitory effects within the central nervous system. Abrupt discontinuation after chronic use can lead to a withdrawal syndrome similar to that seen with alcohol or benzodiazepines.
Management
Treatment is supportive, with close monitoring of airway, breathing, and circulation. Mechanical ventilation may be required in cases of significant respiratory depression.
Key Points
Source
Baclofen is a prescription muscle relaxant used to treat spasticity in conditions such as spinal cord injury, cerebral palsy, and multiple sclerosis. It is available in oral form and can also be administered via intrathecal pumps for targeted delivery.
Typical Presentation
Toxicity may occur following overdose or misuse. Patients often present with progressive central nervous system depression, which may initially resemble intoxication and later advance to severe neurological impairment.
Clinical Features
Findings are consistent with a sedative-hypnotic toxidrome. Symptoms include drowsiness, poor coordination, ataxia, slurred speech, nausea, vomiting, and altered mental status. Cardiovascular effects may include either low or high blood pressure and slow or fast heart rate. Neurologically, decreased reflexes, muscle relaxation, coma, seizures, apnea, and respiratory arrest can occur. In some cases, paradoxical muscle rigidity or spasms may be seen. Severe toxicity is more likely with large ingestions and may require prolonged intensive care support.
Mechanism of Action
Baclofen acts as a GABA(B) receptor agonist, producing inhibitory effects within the central nervous system. Abrupt discontinuation after chronic use can lead to a withdrawal syndrome similar to that seen with alcohol or benzodiazepines.
Management
Treatment is supportive, with close monitoring of airway, breathing, and circulation. Mechanical ventilation may be required in cases of significant respiratory depression.
Key Points
- High doses are associated with severe CNS depression, seizures, and prolonged coma.
- Baclofen toxicity can sometimes mimic brain death.
- The drug has potential for misuse due to its sedative and euphoric effects.
- Intrathecal administration requires much smaller doses compared to oral use.
- Published on
Toxicology – Carisoprodol Toxicity
Source
Carisoprodol is a centrally acting skeletal muscle relaxant, often prescribed alone or in combination with other agents such as aspirin or codeine. It has a relatively rapid onset (about 30 minutes) and a short duration of action. The drug is metabolized into meprobamate, an active compound with sedative properties.
Typical Presentation
Patients may present with overdose or misuse, often in combination with other substances such as opioids or alcohol. Requests for specific medications and recurrent visits may raise suspicion for misuse.
Clinical Features
Toxicity produces features of a sedative-hypnotic syndrome. Symptoms include central nervous system depression, drowsiness, poor coordination, ataxia, slurred speech, nausea, vomiting, hypotension, and bradycardia. Severe cases may progress to coma, seizures, respiratory depression, or arrest. Some patients may paradoxically exhibit increased muscle tone, hyperreflexia, or abnormal posturing.
Mechanism of Action
Carisoprodol and its metabolite meprobamate enhance activity at GABA(A) receptors, producing sedative effects similar to barbiturates. Abrupt discontinuation after chronic use can lead to withdrawal symptoms resembling those seen with alcohol or benzodiazepines.
Management
Treatment is supportive, with attention to airway protection, breathing, and circulation. Monitoring is essential, especially in cases of suspected coingestion with other central nervous system depressants.
Key Points
Source
Carisoprodol is a centrally acting skeletal muscle relaxant, often prescribed alone or in combination with other agents such as aspirin or codeine. It has a relatively rapid onset (about 30 minutes) and a short duration of action. The drug is metabolized into meprobamate, an active compound with sedative properties.
Typical Presentation
Patients may present with overdose or misuse, often in combination with other substances such as opioids or alcohol. Requests for specific medications and recurrent visits may raise suspicion for misuse.
Clinical Features
Toxicity produces features of a sedative-hypnotic syndrome. Symptoms include central nervous system depression, drowsiness, poor coordination, ataxia, slurred speech, nausea, vomiting, hypotension, and bradycardia. Severe cases may progress to coma, seizures, respiratory depression, or arrest. Some patients may paradoxically exhibit increased muscle tone, hyperreflexia, or abnormal posturing.
Mechanism of Action
Carisoprodol and its metabolite meprobamate enhance activity at GABA(A) receptors, producing sedative effects similar to barbiturates. Abrupt discontinuation after chronic use can lead to withdrawal symptoms resembling those seen with alcohol or benzodiazepines.
Management
Treatment is supportive, with attention to airway protection, breathing, and circulation. Monitoring is essential, especially in cases of suspected coingestion with other central nervous system depressants.
Key Points
- Frequently abused due to its sedative and euphoric effects.
- Often taken in combination with opioids or alcohol, increasing risk of severe toxicity.
- Withdrawal can occur with abrupt cessation after prolonged use.
- Published on
Toxicology – Nonsteroidal Anti-Inflammatory Drug (NSAID) Toxicity
Source
NSAIDs are widely used medications for pain relief, inflammation, and fever reduction. Ibuprofen is the most commonly encountered agent. Other examples include diclofenac, naproxen, indomethacin, ketorolac, meloxicam, and sulindac.
Typical Presentation
Most cases involve mild overdose, often in young individuals, presenting with gastrointestinal discomfort. Severe toxicity is uncommon but may occur with large ingestions.
Clinical Features
Symptoms are usually mild and include abdominal pain, nausea, and vomiting. Occasionally, patients may develop gastrointestinal bleeding. In more severe overdoses, complications can include acute kidney injury, hyperkalemia, tinnitus, seizures, coma, or cardiovascular collapse. Symptoms typically begin within a few hours of ingestion and resolve within 24 hours in uncomplicated cases.
Mechanism of Action
NSAIDs inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin production. While this provides therapeutic effects, it can also impair kidney function and damage the gastrointestinal lining, especially with high doses or prolonged use.
Management
Treatment is supportive. Intravenous fluids and antiemetics are commonly used. There is no specific antidote. Patients with mild symptoms and stable vital signs may be observed for several hours and discharged if no complications develop.
Key Points
Source
NSAIDs are widely used medications for pain relief, inflammation, and fever reduction. Ibuprofen is the most commonly encountered agent. Other examples include diclofenac, naproxen, indomethacin, ketorolac, meloxicam, and sulindac.
Typical Presentation
Most cases involve mild overdose, often in young individuals, presenting with gastrointestinal discomfort. Severe toxicity is uncommon but may occur with large ingestions.
Clinical Features
Symptoms are usually mild and include abdominal pain, nausea, and vomiting. Occasionally, patients may develop gastrointestinal bleeding. In more severe overdoses, complications can include acute kidney injury, hyperkalemia, tinnitus, seizures, coma, or cardiovascular collapse. Symptoms typically begin within a few hours of ingestion and resolve within 24 hours in uncomplicated cases.
Mechanism of Action
NSAIDs inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin production. While this provides therapeutic effects, it can also impair kidney function and damage the gastrointestinal lining, especially with high doses or prolonged use.
Management
Treatment is supportive. Intravenous fluids and antiemetics are commonly used. There is no specific antidote. Patients with mild symptoms and stable vital signs may be observed for several hours and discharged if no complications develop.
Key Points
- Most acute NSAID overdoses are mild and self-limiting.
- Serious toxicity is more likely with very high doses (e.g., >400 mg/kg).
- Use caution in elderly patients and those with kidney disease, even at normal doses.
- Chronic overuse increases the risk of gastrointestinal bleeding and renal injury.
- Published on
Toxicology – Salicylate Toxicity
Source
Salicylates are present in many over-the-counter and prescription medications used for pain, fever, and inflammation. Common sources include aspirin, methyl salicylate (oil of wintergreen), combination cold remedies, topical analgesics, bismuth subsalicylate (e.g., Pepto-Bismol), and effervescent formulations like Alka-Seltzer.
Typical Presentation
Toxicity may occur acutely after a large ingestion or chronically from repeated high dosing, especially in elderly patients. Acute cases often present with gastrointestinal and auditory symptoms, whereas chronic toxicity may present more subtly.
Clinical Features
Acute Toxicity
Patients commonly develop nausea, vomiting, abdominal pain, rapid breathing (tachypnea), ringing in the ears (tinnitus), and confusion. Severe cases may progress to hypoglycemia, seizures, pulmonary edema, and coma. A classic finding is a mixed acid–base disorder: respiratory alkalosis combined with metabolic acidosis.
Chronic Toxicity
Typically seen in older individuals, presenting with confusion, dehydration, and metabolic acidosis. Symptoms are often nonspecific and can mimic other illnesses, making diagnosis more challenging.
Mechanism of Action
Salicylates stimulate the respiratory center in the brain, causing hyperventilation and respiratory alkalosis. They also uncouple oxidative phosphorylation, leading to increased acid production and metabolic acidosis. Additionally, they irreversibly inhibit cyclooxygenase (COX) enzymes.
Management
Treatment is supportive and includes careful monitoring. If intubation is required, maintaining adequate hyperventilation is critical to prevent worsening acidosis. Sodium bicarbonate is administered to alkalinize the blood (target pH ≥7.4) and urine (target pH 7.5–8.5), which enhances salicylate elimination.
Gastrointestinal decontamination with multiple-dose activated charcoal or whole bowel irrigation may be considered. Hemodialysis is indicated in severe toxicity, particularly with high salicylate levels or significant clinical deterioration. Patients should also be monitored for complications such as pulmonary edema.
Key Points
Source
Salicylates are present in many over-the-counter and prescription medications used for pain, fever, and inflammation. Common sources include aspirin, methyl salicylate (oil of wintergreen), combination cold remedies, topical analgesics, bismuth subsalicylate (e.g., Pepto-Bismol), and effervescent formulations like Alka-Seltzer.
Typical Presentation
Toxicity may occur acutely after a large ingestion or chronically from repeated high dosing, especially in elderly patients. Acute cases often present with gastrointestinal and auditory symptoms, whereas chronic toxicity may present more subtly.
Clinical Features
Acute Toxicity
Patients commonly develop nausea, vomiting, abdominal pain, rapid breathing (tachypnea), ringing in the ears (tinnitus), and confusion. Severe cases may progress to hypoglycemia, seizures, pulmonary edema, and coma. A classic finding is a mixed acid–base disorder: respiratory alkalosis combined with metabolic acidosis.
Chronic Toxicity
Typically seen in older individuals, presenting with confusion, dehydration, and metabolic acidosis. Symptoms are often nonspecific and can mimic other illnesses, making diagnosis more challenging.
Mechanism of Action
Salicylates stimulate the respiratory center in the brain, causing hyperventilation and respiratory alkalosis. They also uncouple oxidative phosphorylation, leading to increased acid production and metabolic acidosis. Additionally, they irreversibly inhibit cyclooxygenase (COX) enzymes.
Management
Treatment is supportive and includes careful monitoring. If intubation is required, maintaining adequate hyperventilation is critical to prevent worsening acidosis. Sodium bicarbonate is administered to alkalinize the blood (target pH ≥7.4) and urine (target pH 7.5–8.5), which enhances salicylate elimination.
Gastrointestinal decontamination with multiple-dose activated charcoal or whole bowel irrigation may be considered. Hemodialysis is indicated in severe toxicity, particularly with high salicylate levels or significant clinical deterioration. Patients should also be monitored for complications such as pulmonary edema.
Key Points
- Chronic toxicity is often missed due to nonspecific symptoms.
- Mixed respiratory alkalosis and metabolic acidosis is a hallmark finding.
- Oil of wintergreen is highly concentrated and potentially lethal, especially in children.
- Chronic toxicity generally carries a worse prognosis than acute overdose.
- Adequate ventilation must be maintained in intubated patients.
- Published on
Toxicology – Acetaminophen (Paracetamol) Toxicity
Source
Acetaminophen is a commonly used over-the-counter medication for pain relief and fever reduction. It is available as a single agent and is frequently combined with other drugs, including opioids and “cold and flu” preparations. In adults, doses below 4 grams per day are generally considered safe.
Typical Presentation
Patients may present after intentional or accidental overdose. Early on, individuals often appear well, which can make diagnosis challenging without a clear history.
Clinical Features
In the initial phase, symptoms may be minimal or limited to mild nausea and vomiting. Within 24–48 hours, laboratory abnormalities begin to appear, including elevated liver enzymes (ALT, AST) and prolonged coagulation times (PT/PTT). As toxicity progresses, patients may develop altered mental status, metabolic acidosis, liver failure, and kidney injury. Severe cases can lead to encephalopathy and death.
Mechanism of Action
Acetaminophen is metabolized primarily through glucuronidation and sulfation. A smaller portion is metabolized via the cytochrome P450 system, producing a toxic metabolite (NAPQI). Under normal conditions, NAPQI is neutralized by glutathione. In overdose, glutathione stores are depleted, allowing NAPQI to accumulate and cause liver cell damage.
Management
An acetaminophen level should be measured approximately 4 hours after ingestion and interpreted using the Rumack-Matthew nomogram. If levels fall within the treatment range, N-acetylcysteine (NAC) should be administered. NAC acts as a glutathione substitute and helps detoxify the harmful metabolite. It is most effective when given early but can still be beneficial later in the course. NAC is available in both oral and intravenous forms. Severe liver failure may require liver transplantation.
Key Points
Source
Acetaminophen is a commonly used over-the-counter medication for pain relief and fever reduction. It is available as a single agent and is frequently combined with other drugs, including opioids and “cold and flu” preparations. In adults, doses below 4 grams per day are generally considered safe.
Typical Presentation
Patients may present after intentional or accidental overdose. Early on, individuals often appear well, which can make diagnosis challenging without a clear history.
Clinical Features
In the initial phase, symptoms may be minimal or limited to mild nausea and vomiting. Within 24–48 hours, laboratory abnormalities begin to appear, including elevated liver enzymes (ALT, AST) and prolonged coagulation times (PT/PTT). As toxicity progresses, patients may develop altered mental status, metabolic acidosis, liver failure, and kidney injury. Severe cases can lead to encephalopathy and death.
Mechanism of Action
Acetaminophen is metabolized primarily through glucuronidation and sulfation. A smaller portion is metabolized via the cytochrome P450 system, producing a toxic metabolite (NAPQI). Under normal conditions, NAPQI is neutralized by glutathione. In overdose, glutathione stores are depleted, allowing NAPQI to accumulate and cause liver cell damage.
Management
An acetaminophen level should be measured approximately 4 hours after ingestion and interpreted using the Rumack-Matthew nomogram. If levels fall within the treatment range, N-acetylcysteine (NAC) should be administered. NAC acts as a glutathione substitute and helps detoxify the harmful metabolite. It is most effective when given early but can still be beneficial later in the course. NAC is available in both oral and intravenous forms. Severe liver failure may require liver transplantation.
Key Points
- Early stages may be asymptomatic despite significant toxicity.
- Always consider acetaminophen exposure in mixed or unknown overdoses.
- The nomogram is not reliable for chronic ingestion or certain extended-release formulations.
- Toxic doses are generally ≥7.5 g in adults and ≥140 mg/kg in children.
- Published on
Toxicology – Alpha-Blocker Toxicity
Source
Alpha-adrenergic blockers include medications such as prazosin, terazosin, doxazosin, and tamsulosin. These drugs are used in the management of hypertension, benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), and certain anxiety conditions.
Typical Presentation
Toxicity often presents with episodes of dizziness or fainting, especially after standing. Patients may report weakness and lightheadedness following overdose or excessive dosing.
Clinical Features
Common symptoms include orthostatic (postural) hypotension, dizziness, syncope, headache, nausea, generalized weakness, palpitations, and reflex tachycardia. These effects are primarily due to vasodilation and reduced vascular tone.
Mechanism of Action
Alpha-blockers inhibit alpha-adrenergic receptors. Blockade of α1 receptors leads to relaxation of vascular smooth muscle, resulting in decreased peripheral resistance and blood pressure. This vasodilation causes venous pooling, particularly when standing, leading to orthostatic hypotension. Because there is no direct suppression of cardiac function, the body compensates with reflex tachycardia.
Management
Treatment is supportive. Intravenous fluids are used to restore circulating volume. Positioning the patient supine or in the Trendelenburg position can help improve blood pressure. Activated charcoal may be considered in early presentations.
Key Points
Source
Alpha-adrenergic blockers include medications such as prazosin, terazosin, doxazosin, and tamsulosin. These drugs are used in the management of hypertension, benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), and certain anxiety conditions.
Typical Presentation
Toxicity often presents with episodes of dizziness or fainting, especially after standing. Patients may report weakness and lightheadedness following overdose or excessive dosing.
Clinical Features
Common symptoms include orthostatic (postural) hypotension, dizziness, syncope, headache, nausea, generalized weakness, palpitations, and reflex tachycardia. These effects are primarily due to vasodilation and reduced vascular tone.
Mechanism of Action
Alpha-blockers inhibit alpha-adrenergic receptors. Blockade of α1 receptors leads to relaxation of vascular smooth muscle, resulting in decreased peripheral resistance and blood pressure. This vasodilation causes venous pooling, particularly when standing, leading to orthostatic hypotension. Because there is no direct suppression of cardiac function, the body compensates with reflex tachycardia.
Management
Treatment is supportive. Intravenous fluids are used to restore circulating volume. Positioning the patient supine or in the Trendelenburg position can help improve blood pressure. Activated charcoal may be considered in early presentations.
Key Points
- Orthostatic hypotension is a hallmark feature of toxicity.
- Reflex tachycardia occurs due to compensatory mechanisms.
- Tamsulosin is more selective for α1 receptors in the urinary tract and typically has less effect on systemic blood pressure at therapeutic doses.
- Published on
Toxicology – ACE Inhibitor Toxicity
Source
Angiotensin-converting enzyme (ACE) inhibitors include medications such as captopril, enalapril, lisinopril, ramipril, quinapril, fosinopril, benazepril, moexipril, and trandolapril. They are widely used to treat hypertension, heart failure, and diabetic kidney disease.
Typical Presentation
Toxicity may occur due to accidental or intentional overdose, particularly in elderly patients with multiple medications. Patients commonly present with low blood pressure and electrolyte abnormalities.
Clinical Features
Key findings include hypotension, acute kidney injury (manifesting as reduced urine output or elevated creatinine), and hyperkalemia. Elevated potassium levels can lead to cardiac conduction abnormalities and arrhythmias. In some cases, bradycardia may occur. Even at therapeutic doses, ACE inhibitors may cause cough, wheezing, and angioedema.
Mechanism of Action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction and lower blood pressure. They also increase levels of bradykinin, which contributes to side effects such as cough and angioedema.
Management
Treatment is supportive. Intravenous fluids are typically effective for hypotension. Continuous cardiac monitoring and ECG evaluation are recommended. Laboratory monitoring should include kidney function and serum potassium. Activated charcoal may be considered in early presentations.
Hyperkalemia should be treated as indicated, using measures such as insulin with glucose, beta-agonists, potassium-binding agents, or dialysis in severe cases. Calcium gluconate or calcium chloride is used to stabilize cardiac membranes when ECG changes are present.
Angioedema requires immediate discontinuation of the drug and treatment with supportive measures, including antihistamines and corticosteroids. Airway protection may be necessary in severe cases.
Key Points
Source
Angiotensin-converting enzyme (ACE) inhibitors include medications such as captopril, enalapril, lisinopril, ramipril, quinapril, fosinopril, benazepril, moexipril, and trandolapril. They are widely used to treat hypertension, heart failure, and diabetic kidney disease.
Typical Presentation
Toxicity may occur due to accidental or intentional overdose, particularly in elderly patients with multiple medications. Patients commonly present with low blood pressure and electrolyte abnormalities.
Clinical Features
Key findings include hypotension, acute kidney injury (manifesting as reduced urine output or elevated creatinine), and hyperkalemia. Elevated potassium levels can lead to cardiac conduction abnormalities and arrhythmias. In some cases, bradycardia may occur. Even at therapeutic doses, ACE inhibitors may cause cough, wheezing, and angioedema.
Mechanism of Action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction and lower blood pressure. They also increase levels of bradykinin, which contributes to side effects such as cough and angioedema.
Management
Treatment is supportive. Intravenous fluids are typically effective for hypotension. Continuous cardiac monitoring and ECG evaluation are recommended. Laboratory monitoring should include kidney function and serum potassium. Activated charcoal may be considered in early presentations.
Hyperkalemia should be treated as indicated, using measures such as insulin with glucose, beta-agonists, potassium-binding agents, or dialysis in severe cases. Calcium gluconate or calcium chloride is used to stabilize cardiac membranes when ECG changes are present.
Angioedema requires immediate discontinuation of the drug and treatment with supportive measures, including antihistamines and corticosteroids. Airway protection may be necessary in severe cases.
Key Points
- Angioedema can occur unpredictably, even after prolonged use.
- Chronic dry cough is a common side effect of ACE inhibitors.
- Angiotensin receptor blockers (ARBs) are less likely to cause cough or angioedema.
- Published on
Toxicology – Clonidine Toxicity
Source
Clonidine is available as oral tablets and transdermal patches. It is commonly prescribed for hypertension, attention-deficit/hyperactivity disorder (ADHD), and management of opioid withdrawal.
Typical Presentation
Toxicity often occurs after accidental ingestion, particularly in children. Patients may present with rapid onset of sedation and cardiovascular depression.
Clinical Features
Key findings include hypotension, bradycardia, slow respiratory rate (bradypnea), hypothermia, pinpoint pupils (miosis), and altered mental status ranging from lethargy to coma. A brief phase of elevated blood pressure may occur early due to peripheral receptor effects.
Mechanism of Action
Clonidine is a central alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased heart rate and blood pressure. In overdose, its lipophilic nature allows rapid central nervous system penetration. Transient hypertension may occur initially due to stimulation of peripheral alpha-1 receptors before central effects dominate.
Management
Treatment is supportive and includes close monitoring of cardiac and respiratory status. Airway protection and intravenous fluids are essential. Most cases improve within 24 hours. High-dose naloxone may be beneficial in some patients. Whole bowel irrigation should be considered if a transdermal patch has been ingested.
Key Points
Source
Clonidine is available as oral tablets and transdermal patches. It is commonly prescribed for hypertension, attention-deficit/hyperactivity disorder (ADHD), and management of opioid withdrawal.
Typical Presentation
Toxicity often occurs after accidental ingestion, particularly in children. Patients may present with rapid onset of sedation and cardiovascular depression.
Clinical Features
Key findings include hypotension, bradycardia, slow respiratory rate (bradypnea), hypothermia, pinpoint pupils (miosis), and altered mental status ranging from lethargy to coma. A brief phase of elevated blood pressure may occur early due to peripheral receptor effects.
Mechanism of Action
Clonidine is a central alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased heart rate and blood pressure. In overdose, its lipophilic nature allows rapid central nervous system penetration. Transient hypertension may occur initially due to stimulation of peripheral alpha-1 receptors before central effects dominate.
Management
Treatment is supportive and includes close monitoring of cardiac and respiratory status. Airway protection and intravenous fluids are essential. Most cases improve within 24 hours. High-dose naloxone may be beneficial in some patients. Whole bowel irrigation should be considered if a transdermal patch has been ingested.
Key Points
- Clonidine toxicity can resemble opioid overdose due to sedation and pinpoint pupils.
- Early transient hypertension may precede hypotension.
- Abrupt discontinuation in chronic users can lead to rebound hypertension.
- Published on
Toxicology – Beta-Blocker Toxicity
Source
Beta-blockers include medications such as propranolol, metoprolol, atenolol, nadolol, pindolol, labetalol, and carvedilol. These drugs are commonly used to manage hypertension, cardiac arrhythmias, angina, migraines, and anxiety-related conditions.
Typical Presentation
Toxicity may occur after accidental ingestion (especially in children) or intentional overdose. Patients often present with cardiovascular depression and altered mental status.
Clinical Features
Common findings include bradycardia, hypotension, and varying degrees of heart block. More severe toxicity may lead to ventricular arrhythmias, seizures (especially with propranolol), and central nervous system depression. Additional features can include widened QRS complexes (notably with propranolol), QT prolongation (e.g., with sotalol), and hypoglycemia.
Mechanism of Action
Beta-blockers inhibit β-adrenergic receptors. Blockade of β1 receptors reduces heart rate and contractility, leading to decreased cardiac output. β2 receptor blockade can result in bronchoconstriction. Lipophilic agents, particularly propranolol, cross the blood–brain barrier and can cause central nervous system effects such as sedation, confusion, and seizures.
Management
Treatment is supportive with continuous cardiac monitoring. Interventions may include intravenous fluids, glucagon (to increase intracellular cAMP independent of β-receptors), high-dose insulin therapy with glucose, vasopressors, and cardiac pacing if needed. Sodium bicarbonate may be used for QRS widening, and magnesium for QT prolongation. Lipid emulsion therapy can be considered in severe cases. Bronchodilators are used if bronchospasm develops. Whole bowel irrigation may be indicated for sustained-release ingestions.
Key Points
Source
Beta-blockers include medications such as propranolol, metoprolol, atenolol, nadolol, pindolol, labetalol, and carvedilol. These drugs are commonly used to manage hypertension, cardiac arrhythmias, angina, migraines, and anxiety-related conditions.
Typical Presentation
Toxicity may occur after accidental ingestion (especially in children) or intentional overdose. Patients often present with cardiovascular depression and altered mental status.
Clinical Features
Common findings include bradycardia, hypotension, and varying degrees of heart block. More severe toxicity may lead to ventricular arrhythmias, seizures (especially with propranolol), and central nervous system depression. Additional features can include widened QRS complexes (notably with propranolol), QT prolongation (e.g., with sotalol), and hypoglycemia.
Mechanism of Action
Beta-blockers inhibit β-adrenergic receptors. Blockade of β1 receptors reduces heart rate and contractility, leading to decreased cardiac output. β2 receptor blockade can result in bronchoconstriction. Lipophilic agents, particularly propranolol, cross the blood–brain barrier and can cause central nervous system effects such as sedation, confusion, and seizures.
Management
Treatment is supportive with continuous cardiac monitoring. Interventions may include intravenous fluids, glucagon (to increase intracellular cAMP independent of β-receptors), high-dose insulin therapy with glucose, vasopressors, and cardiac pacing if needed. Sodium bicarbonate may be used for QRS widening, and magnesium for QT prolongation. Lipid emulsion therapy can be considered in severe cases. Bronchodilators are used if bronchospasm develops. Whole bowel irrigation may be indicated for sustained-release ingestions.
Key Points
- Lipophilic beta-blockers can cause early and significant central nervous system depression.
- Hypoglycemia is more commonly seen compared to calcium channel blocker toxicity.
- Bronchospasm may occur, particularly in patients with underlying respiratory disease.
- Published on
Toxicology – Calcium Channel Blocker Toxicity
Source
Calcium channel blockers (CCBs) include medications such as verapamil, diltiazem, amlodipine, nifedipine, nicardipine, and felodipine. These drugs are commonly prescribed for conditions like hypertension, arrhythmias, angina, migraines, and Raynaud’s phenomenon.
Typical Presentation
Toxicity often occurs after accidental ingestion, especially in children, or intentional overdose. Patients may present with cardiovascular instability along with gastrointestinal symptoms.
Clinical Features
Key findings include bradycardia, varying degrees of heart block, hypotension, nausea, vomiting, constipation, and ileus. Hyperglycemia is a distinguishing feature due to impaired insulin release. Severe cases may involve altered mental status secondary to reduced cerebral perfusion.
Mechanism of Action
CCBs inhibit L-type calcium channels in cardiac and smooth muscle. In vascular smooth muscle, this leads to vasodilation and hypotension. In the heart, they decrease sinoatrial and atrioventricular nodal conduction (negative chronotropic effect) and reduce contractility (negative inotropic effect). In pancreatic cells, calcium channel blockade decreases insulin secretion, resulting in elevated blood glucose levels.
Management
Treatment is supportive and requires close cardiac monitoring. Interventions may include intravenous fluids, calcium (calcium gluconate or calcium chloride), high-dose insulin therapy with glucose supplementation, glucagon, vasopressors, and lipid emulsion therapy in severe cases. Whole bowel irrigation may be considered for sustained-release ingestions. Advanced measures such as transvenous pacing or intra-aortic balloon pump support may be required in refractory cases.
Key Points
Source
Calcium channel blockers (CCBs) include medications such as verapamil, diltiazem, amlodipine, nifedipine, nicardipine, and felodipine. These drugs are commonly prescribed for conditions like hypertension, arrhythmias, angina, migraines, and Raynaud’s phenomenon.
Typical Presentation
Toxicity often occurs after accidental ingestion, especially in children, or intentional overdose. Patients may present with cardiovascular instability along with gastrointestinal symptoms.
Clinical Features
Key findings include bradycardia, varying degrees of heart block, hypotension, nausea, vomiting, constipation, and ileus. Hyperglycemia is a distinguishing feature due to impaired insulin release. Severe cases may involve altered mental status secondary to reduced cerebral perfusion.
Mechanism of Action
CCBs inhibit L-type calcium channels in cardiac and smooth muscle. In vascular smooth muscle, this leads to vasodilation and hypotension. In the heart, they decrease sinoatrial and atrioventricular nodal conduction (negative chronotropic effect) and reduce contractility (negative inotropic effect). In pancreatic cells, calcium channel blockade decreases insulin secretion, resulting in elevated blood glucose levels.
Management
Treatment is supportive and requires close cardiac monitoring. Interventions may include intravenous fluids, calcium (calcium gluconate or calcium chloride), high-dose insulin therapy with glucose supplementation, glucagon, vasopressors, and lipid emulsion therapy in severe cases. Whole bowel irrigation may be considered for sustained-release ingestions. Advanced measures such as transvenous pacing or intra-aortic balloon pump support may be required in refractory cases.
Key Points
- Mental status may initially remain normal despite significant cardiovascular compromise.
- Hyperglycemia helps differentiate CCB toxicity from beta-blocker overdose.
- ECG findings may include PR prolongation, sinus arrest, or high-grade heart block.
- Atropine may be attempted for bradycardia but is often ineffective.
